Current partner codePEPTIDESDE
NCT00589134·Not applicable·INTERVENTIONAL

The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

Status

Completed

Phase

Not applicable

Enrollment

26

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Women are at greater risk for exercise-induced hyponatremia (low blood sodium concentration) and this risk has been attributed to their lower body weight and size, excess water ingestion and longer racing times relative to men. While these factors contribute to the greater incidence of hyponatremia in women, it is likely that their greater levels of estradiol in plasma and/or tissue also play a role in increasing the risk of hyponatremia in women. More importantly, estradiol may also leave women more susceptible to the extreme consequences of hyponatremia (i.e. brain damage, death). Hyponatremia is generally attributed to inappropriately elevated levels of the hormone arginine vasopressin (AVP). AVP is the most important hormone controlling water retention in the kidney. Earlier studies in our laboratory have demonstrated that estradiol lowers the threshold for thirst sensation and AVP release during exercise. The purpose of these studies is to test the hypotheses that in women with a history of hyponatremia, estradiol lowers the thresholds for thirst and AVP release, leading to greater fluid retention, lower blood sodium concentration during endurance exercise in the heat. However, we further hypothesize that progesterone administration along with estradiol administration will attenuate the effect of estradiol on the regulation of thirst and AVP, normalize fluid retention, and serum sodium concentration during endurance exercise in the heat. In women without a history of hyponatremia, we expect that estradiol administration will lower the thresholds for thirst and AVP release, but will not increase fluid retention or reduce blood sodium concentration during endurance exercise in the heat. We hypothesize that progesterone administration along with estradiol administration will attenuate the effect of estradiol on thirst and AVP, but have no effect on fluid retention or serum sodium concentration during endurance exercise in the heat. To test these hypotheses, women will perform endurance exercise in the heat under three hormonal conditions: 1) during Gonadotropin-releasing hormone (GnRH) antagonist alone--which will suppress estradiol and progesterone; 2) during GnRH antagonist+estradiol; and 3) during GnRH antagonist+estradiol+ progesterone. During exercise, fluid will be replaced with either water or a carbohydrate-electrolyte beverage (random assignment).

Interventions

Treatment arms and agents.

DIETARY_SUPPLEMENT

Gatorade Endurance Formula

carbohydrate electrolyte beverage

OTHER

ganirelix acetate

GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.

Timeline

From registration to results.

  1. First posted

    Jan 9, 2008

  2. Study start

    Jan 2006

  3. Primary completion

    Dec 2009

  4. Study completion

    Dec 2009

  5. Results posted

    Not reported

  6. Registry updated

    Mar 30, 2020

Outcomes

What the study measures.

Primary outcomes

osmotic regulation of AVP

Time frame · 3 years

Secondary outcomes

temperature responses

Time frame · 3 years

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
35 Years
Sex
FEMALE
Healthy volunteers
Yes

Inclusion Criteria: * healthy volunteers (18-35 yrs) with and without previous exercise induced hyponatremia Exclusion Criteria: * conditions that would preclude safe exercise or safe use of hormones

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

John B. Pierce Laboratory

New Haven, Connecticut, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Ganirelix.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.